Airway diseases
Interstitial lung diseases
Thoracic oncology
Oral presentation
New clinical and biological developments in lung cancer
Aims : This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
This session includes the Best Abstract for Assembly 11.01 - Lung cancer, entitled "Spirometry and under-diagnosis of COPD in a lung cancer screening cohort”
Methods :
Pulmonary function testing, Cell and molecular biology, Epidemiology, Endoscopy and interventional pulmonology, Imaging, General respiratory patient care
11:15
Introduction
1
OA4314
11:20
Spirometry and under-diagnosis of COPD in a lung cancer screening cohort
C. Bradley(letterkenny, Ireland)
COI
2
11:25
Application of breathomics in early detection of lung cancer in indian population: a pilot study
B. Pattnaik(NEW DELHI, India)
COI
3
11:30
Validation of lung nodule detection a year before diagnosis in NLST dataset based on a deep learning system
H. Delingette(sophia antipolis, France)
COI
4
11:35
Clinical and molecular analysis of lung cancer associated with fibrosing and diffuse interstitial lung disease.
V. Heluain(Toulouse, France)
COI
5
11:40
Instant on-site histological feedback on bronchoscopic biopsies using higher harmonic generation microscopy
L. Van Huizen(Amsterdam, Netherlands)
COI
6
11:45
LSC - 2021 - cAMP response element-binding protein mediates immune-evasion of KRAS-mutant lung adenocarcinoma
G. Giotopoulou(Munich, Germany)
COI
7
11:50
LSC - 2021 - Mutational RNA signatures in environmentally-induced lung adenocarcinoma
G. Giotopoulou(Munich, Germany)
COI
8
11:55
The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors
A. Szpechciński(Warszawa, Poland)
COI
9
12:00
Identification of predictive biomarkers of immunotherapy response in non-small cell lung cancer by multiparametric analysis
J. Ramos Paradas(Madrid, Spain)
COI
10
12:05
Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.
R. Gijtenbeek(Leeuwarden, Netherlands)
COI
11
12:10
Discussion
12
OA4325
. . .
